1. European Commission. Off. J. Eur. Union L136, 34–57 (2004).
2. Health, I.M.S. Shaping the Biosimilars Opportunity: a Global Perspective on the Evolving Biosimilars Landscape (IMS Health, New York, USA, 2011; accessed 11 April 2012). < http://www.imshealth.com/ims/Global/Content/Home%20Page%20Content/IMS%20News/Biosimilars_Whitepaper.pdf >
3. European Medicines Agency. Volume 9A of The Rules Governing Medicinal Products in the European Union. (EMA, London, 2008; accessed 2 August 2012). < http://ec.europa.eu/health/files/eudralex/vol-9/pdf/vol9a_09-2008_en.pdf >
4. European Commission. Off. J. Eur. Union L311, 67–267 (2001).
5. European Medicines Agency. Guideline on Immunogenicity Assessment of Biotechnology-Derived Therapeutic Proteins (EMA, London, 2007; accessed 3 July 2012). < http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003947.pdf >